Introduction
New technologies that are simple, 'off-the-shelf' and potent enough to elicit objective responses in measurable disease, would greatly accelerate the development of next generation active immunotherapies for cancer. One approach can be derived following Zinkernagel's antigen localization hypothesis, that antigens need to reach T cell areas within secondary lymphoid organs to efficiently overcome possible T cell tolerance (1, 2) .
Preclinical studies demonstrated that intra-lymph node administration of tumor antigen epitopes, together with co-stimulation through toll-like receptor (TLR) ligands, resulted in potent T cell immunity and anti-tumor activity (3, 4) . In addition, other preclinical studies showed that intranodal DNA plasmid immunization achieved effective a significantly elevated immune response, as compared to subcutaneous administration or other dosing regimens (5, 6) . This translated into more than 10% of CD8 + T cells being specific to the immunizing epitopes in blood and secondary lymphoid organs, in this preclinical model. In addition, co-induction of robust immunity -in the same preclinical model -against both Melan A and tyrosinase, two well recognized melanoma associated antigens (8, 9) , was also achieved using this approach (6) .
Previous clinical evidence supported the safety and feasibility of direct intra-lymph node administration, with only mild-to-moderate therapy-related adverse events such as flu-like syndrome (10) (11) (12) . However, such early phase trials with individual plasmids expressing immunogenic portions of tyrosinase (11) and Melan A (12) in patients with advanced melanoma, showed a modest immune response rate of ~20%, with no objective tumor responses or evidence of disease control. Thus, we hypothesized that a heterologous plasmid primingpeptide boosting would result in enhanced biological and evidence of clinical benefit. Taking into account the Th1/Tc1-biasing activity of plasmids carrying immune stimulatory sequences (ISSs) (13, 14) , we tested a simple boosting strategy using peptides with no adjuvant, also delivered into non-diseased lymph nodes. To optimize the immune activity, the plasmid was previously optimized to preferentially yield immunodominant HLA-A2-restricted epitopes from Melan A and tyrosinase (15, 16). Finally, we utilized boosting peptides that had 8 In this phase 1 clinical trial, as in the previous ones carried out with individual plasmids (11, 12) 
MKC1106-MT Preparation and Administration.
The pMEL-TYR is a recombinant plasmid expressing fragments of two melanoma antigens, Melan A and tyrosinase (described previously as pSEM; Fig. 1A patients were categorized as lymphatic metastatic disease (M1a): 2 in the low and 4 in the high peptide dose cohort. Upon detailed retrospective analysis of the baseline imaging scans, these patients showed a few small lesions within visceral organs, of unclear significance. Seven patients (39%) had received prior chemotherapy; 11 patients (61%) had received immunotherapy and one (5%) had undergone radiation therapy, prior to participating to this trial.
Tumor evaluation for antigen expression at baseline. The expression of the target antigens (Melan A and tyrosinase) and of β2-microglobulin (a surrogate for MHC class I expression) was determined in tumor biopsies collected before treatment, by standard IHC (Suppl. 
patients (39%) had mild, treatment-related adverse events. The most frequently reported AEs in both low and high peptide dose cohorts were fatigue (39%), hyponatremia (28%), chills (22%), constipation (22%), diarrhea (22%) and hypoalbuminemia (22%). In total, 4 patients (3 in the low dose cohort and one in the high dose cohort) died while on study or within the follow-up period, all due to disease progression.
To evaluate the accumulation, clearance and/or persistence of the DNA component (pMEL-TYR) of the study regimen, a standard quantitative PCR analysis using specific primers was performed on blood samples at screening, on day 18 of each cycle and at the final visit. As expected, no detectable levels of pMEL-TYR were present at screening. Plasmid levels in the peripheral blood were low or not detectable in most patients over the course of treatment. One patient (881-0006) had transient, high plasmid levels during cycles 2 and 4, with the highest level reported at 1.96 million copies per μg of genomic DNA.
However, at the end of the study, there was no evidence of plasmid in blood.
Only one patient (881-0021) had detectable levels of pMEL-TYR plasmid at the end of the trial, one week after the completion of the immunization regimen.
Clinical Evaluation. Among the 18 patients treated (7 in the low peptide dose cohort and 11 in the high dose cohort, respectively), 6 patients (1 in the low dose cohort, 5 in the high dose cohort) met the criteria for disease control (SD ≥ 8 weeks or better). Thus, the overall disease control rate was 33% (14% and 46% in the low and high peptide dose group, respectively). These patients had an SD 
progression during the first treatment cycle and the other patient had grade 3 fatigue and was withdrawn from the protocol.
Overall, 9 patients (50%) had an immune response to either Melan A or tyrosinase, according to prospectively set immune response criteria (Table 2 and Methods). Tetramer analysis identified two categories of patients: immune responding and non-responding patients ( Suppl Fig 2) . In the low peptide dose cohort, 3 / 4 evaluable patients had an immune response. All 3 patients mounted a response to Melan A, while one had a response to tyrosinase also. In the high peptide dose cohort, 6 / 10 evaluable patients had an immune response; 4 patients had a response to Melan A and 5 had a response to tyrosinase. One and 3 patients in the low and high peptide dose respectively, mounted a response against both antigens. Only one patient in this study had an ELISPOT response: patient (881-0006) in the high dose cohort, who had a response to Melan A and showed radiological evidence of tumor regression also (Suppl Figs.
1, 2).
Correlation Between Immunity and Clinical Evolution. Of the 4 patients with durable disease control and radiological evidence of tumor regression, only 2 patients (881-0006 and 881-0020) showed an immune response manifested by an expansion of antigen specific T cells in blood, against both immunizing antigens (Fig. 2, Suppl Figs. 1, 4) . Of the remaining 14 patients, only 2 developed immunity against both immunizing antigens. Three other patients in and evidence of tumor regression, mounted a quite sustained response against tyrosinase 369-377 , as measured by induction and expansion of tyrosinase-specific T cell population in blood. 
Analysis of T Cells in Tumor Biopsies
that the dosing regimen needs optimization or addition of adjuvants.
Nevertheless, interestingly, the proportion of patients that showed an immune response to tyrosinase was higher in the high peptide dose cohort versus the low dose cohort (5/6 vs 1/3 tyrosinase responders / number of evaluable patients who developed immune responses).
This prime-boost regimen also resulted in an at least two-fold higher immune response rate compared to prior trials utilizing the intra-lymph node plasmid immunization (12) . Since there was no significant correlation between the expansion of total TAA-specific T cells in the blood and disease control, we 
